Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome

Journal of Diabetes Science and Technology

Volumn 1, Issue 2, 2007, Pages 211-217

  Steiner, Charles A ^a,b   Janez, Andrej ^c   Jensterle, Mojca ^c   Reisinger, Katrin ^b   Forst, Thomas ^b   Pfützner, Andreas ^b,d  

^a GETTYSBURG COLLEGE   (United States)

^b IKFE Institute for Clinical Research and Development   (Germany)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Adiponectin; Insulin resistance; Metformin; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

EID: 77958000651     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100212     Document Type: Article

References (34)

1. Barber TM, McCarthy MI, Wass J A H, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65(2):137-46.
2. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, indendent of obesity, in polycystic ovary syndrome. Diabetes. 1989 Sep; 38(9):1165-74.
3. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance I polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res. 2001;56:295-308.
4. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome J Clin Endocrinol Metab. 1995;80(9):2585-93.
5. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Frank S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992 Jan; 36(1):105-11.
6. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1626-32.
7. Gilbert C, Valois M, Koren G. Pregnancy outcome after firsttrimester exposure to metformin: a meta-analysis. Fertil Steril. 2006 Sep; 86(3):658-63.
8. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006;86(2):385-97.
9. Schöndorf T, Maiworm A, Emmission N, Forst T, Pfützner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab. 2005;51(9-10):489-94.
10. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infaction in men. JAMA. 2004 Apr. 14;291(14):1730-7.
11. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Ann NY Acad Sci. 1993 Mar. 15;676:270-8.
12. Kissebah AH, Peiris AN. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1989 Mar; 5(2):83-109.
13. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307(5708):426-30.
14. Blaner WS. Retinol binding protein: the serum transport protein for vitamin A. Endocr. 1989 Aug; 10(3):308-16.
15. Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta. 2000 Oct. 18;1482(1-2):57-64.
16. Basualdo CG, Wein EE, Basu TK. Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. J Am Coll Nutr. 1997 Feb; 16(1):39-45.
17. Abahusain MA, Wright J, Dickerson JW, De Vol EB. Retinol, alphatocopherol and carotenoids in diabetes. Eur J Clin Nutr. 1999 Aug; 53(8):630-5.
18. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinolbinding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med. 2006 Jun. 15;354(24):2552-63.
19. Polonsky KS. Retinol-binding protein 4, insulin resistance, and type 2 diabetes. N Engl J Med. 2006 Jun. 15;354(24):2596-8.
20. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Lübben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004 Mar; 27(3):682-7.
21. Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diab Technol Ther. 2004 Jun; 6(3):405-12.
22. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar M A. The hormone resistin links obesity to diabetes. Nature. 2001 Janl8;409(6818):307-12.
23. Pfützner A, Langenfeld M, Kunt T, Löbig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab. 2003;49(11-12):571-6.
24. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell; 1992. p. 377-84.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul; 28(7):412-9.
26. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in nondiabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Med. 2000 Apr; 17(4):299-307.
27. Sharma ST, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab. 2006 Jun; 20(2):245-60.
28. Yang Q, Graham TE, Mody N Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005 Jul. 21;436(7049):356-62.
29. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony enhancement factor in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Jan; 91(1):295-9.
30. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006 Aug; 91(8):3165-70.
31. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst TI. Impact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations: results from a double blind oral combination study with glimepiride. Metabolism. 2006 Jan; 55(1):20-5.
32. Martos-Moreno GA, Barrios V, Soriano-Guillen L, Argente J. Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy. Eur J Endocrinol. 2006 Nov; 155(5):757-61.
33. Forst T, Lübben G, Karagiannis E, Roth W, Pfützner A. PPARy activation increases plasma adiponectin levels. Diabetes Stoffw. Herz 2006;15(5):17-9.
34. Gulcelik NE, Aral Y, Serter R, Demir Y, Culha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2006 Sep; 22(9):511-5.